Cell adhesion molecules

Ymmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, Switzerland, Feb. 28, 2023 /PRNewswire/ -- Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today that it has been granted Orphan Drug Designation (ODD) by the US Food & Drug Administration (FDA) for YB-200, a CEACAM1/5 antibody it is studying for the treatment of hepatocellular carcinoma (HCC). "This designation is an important milestone in our development of CEACAM antibodies as anti-cancer treatments," said Ymmunobio Founder and CEO Katrin Rupalla, PhD. "We're very pleased to continue our investigation into CEACAM antibodies for the treatment of hepatocellular carcinoma." YB-200 belongs to a novel class of CEACAM1 antibodies with a dual action. It acts as a checkpoint inhibitor, but also has a direct immune agonistic effect on immune cells. The antibody is currently in preclinical development. The in vivo anti-tumor data in liver cancer were presented at the SITC 37th Annual Meeting1 in a poster presentation2 entitled "Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment." Hepatocellular carcinoma3 (HCC), or liver cancer, occurs when a tumor grows on the liver. It is responsible for over 12,000 deaths per year in the United States, making it one of the most serious cancers in adults. HCC is most often diagnosed in people aged 50 and over.4 The FDA grants ODD to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. To learn more about Ymmunobio's activities and research, visit the website or reach out to info@ymmuno.bio. *carcinoembryonic antigen-related cell adhesion molecules ABOUT YMMUNOBIO Ymmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments focus on high unmet need indications in gastro-intestinal cancers. Learn more on Ymmunobio's website and follow on LinkedIn. Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio REFERENCES 1 SITC 37th Annual Meeting Abstracts, 2022. Society for Immunotherapy of Cancer. Available at . Accessed February 2023. 2 Journal for Immunotherapy of Cancer, Volume 10, Issue Suppl 2. Accessed February 2023. Available at . Accessed February 2023. 3 Liver Cancer, Johns Hopkins Medicine. Accessed February 2023. 4 Liver Cancer, Hepatocellular Carcinoma, Medline Plus, National Library of Medicine. Available at . Accessed February 2023.

RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, has been selected by BIO-Europe 2022 to present at the Start-up Spotlight session on October 25, 2022 in Leipzig, Germany. The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live pitch competition gives a group of hand-selected startups the opportunity to pitch in front of the BIO-Europe audience. Selected companies will present a four-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner onsite. “We’re looking forward to sharing our findings with this very innovative group,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. Dr. Rupalla will present Ymmunobio’s company focus on enabling new cancer treatments by increasing immune cell communication. BIO-Europe 2022 takes place October 24-26 and attracts a wide range of business leaders, such as: senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. The competition will begin in Multi-purpose Room 3 at 3:30 pm at the Leipzig Messe in Leipzig, Germany, October 25, 2022. ABOUT YMMUNOBIO Ymmunobio AG is a preclinical stage oncology biotech company developing a novel class of CEACAM antibodies to treat cancer. Ymmunobio’s wholly owned CEACAM antibodies directly target immune cell communication, thereby increasing the efficiency of the immune system to fight cancer. Learn more on Ymmunobio’s website and follow on LinkedIn. Media Contact: Kellyann Zuzulo, Director, Communications, 215-287-7291, kellyann@em-press.media Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio

RIEHEN, SWITZERLAND, October 13, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, will present pre-clinical data that shows the anti-cancer activity of its lead asset YB-200 at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA, and virtually on November 8-12, 2022. TITLE: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment. POSTER NUMBER: 1384 PRESENTERS: Dr. Katrin Rupalla, CEO, Ymmunobio AG, and Dr. Bernhard B. Singer, University Essen/Duisburg, Germany DATE/TIME: Friday, November 11, 2022. Posters will be on display in Hall C from 9 a.m. to 9 p.m. EST. The full text of this year’s SITC abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement at 8:00 a.m. EST on Tuesday, Nov. 7, 2022 and available from the SITC website. Co-authors of Ymmunobio’s poster presentation are Michel Janicot, PhD, Ymmunobio, Alexej Schmidt, PhD, University of Umea, Sweden, and Iris Helfrich, PhD, Professor at the University of Munich, Germany. ABOUT YMMUNOBIO Ymmunobio AG is a preclinical stage oncology biotech company developing a novel class of CEACAM antibodies to treat cancer. Ymmunobio’s wholly owned CEACAM antibodies directly target immune cell communication, thereby increasing the efficiency of the immune system to fight cancer. Learn more on Ymmunobio’s website and follow on LinkedIn. Media Contact: Kellyann Zuzulo, Director, Communications, 215-287-7291, kellyann@em-press.media Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio